PharmExec

ABL Bio Enters $2.6 Billion Multi-Program Collaboration Agreement with Eli Lilly

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...